Previous 10 | Next 10 |
Insider buying was lackluster last week with insiders purchasing just $10.39 million of stock last week compared to $54.38 million in the week prior. This is the fourth week in a row we have seen a decline in insider buying and coincides with the earnings related quiet period. We should see a ...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red again last week, falling from 3,324.66 points on Monday’s open to 3,314.13 points as of 1:54 p.m. EDT on Friday (July 19). On Sunday (July 14), Gilead Sciences (NASDAQ: GILD ) announced its plans to play US$5.1 ...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Noteworthy events during the week of July 14 - 20 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Cortexyme, Inc., Cytori Therapeutics, Inc., Healthcare stocks news, , Read more ...
NEW YORK , July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron , Chief Scientific Officer ...
NEW YORK , July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Mr. Xiaoming Gao is joining its board of directors. Mr. Ga...
NEW YORK , July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Mr. Xiaoming Gao is joining its board of directors. Mr. Ga...
Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the treatment of Type 2 diabetes; results expected in 4Q 2019; following results Oramed plan...
NEW YORK , June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business D...
NEW YORK , May 21, 2019 /PRNewswire/ -- ORMD-0801 reaches significant milestone on path to potentially be the first commercial oral insulin capsule for the treatment of Type 2 diabetes Close to 300 patients have now been enrolled. 70% of patients have already completed treatmen...
News, Short Squeeze, Breakout and More Instantly...
Oramed Pharmaceuticals Inc. Company Name:
ORMP Stock Symbol:
NASDAQ Market:
Oramed Pharmaceuticals Inc. Website:
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...